Loading…
Swiss pharmacy retailer and wholesale drug distributor operating Amavita and Sun Store chains plus Galexis logistics.
Swiss pharmacy retailer and wholesale drug distributor operating Amavita and Sun Store chains plus Galexis logistics.
Earns from three activities: retail pharmacy margin at its stores, wholesale margin delivering medicines to independent pharmacies, doctors and hospitals, and fees for storing and shipping drugs for manufacturers. Swiss medicine prices and the distribution margins built into them are set by regulation, so policy changes matter.
In one line: Switzerland's Walgreens plus McKesson combined.
Moat: narrow (scale, distribution). Largest pharmacy network and wholesale logistics scale in Switzerland.
Headquarters: Bern, Switzerland · Employees: 6,558
Size Galenica (GALE.SW) is a Switzerland Health Care company (Medical Distributors) with a market value of $5.46B, the 55th largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 89.45 on 6 Nov 2026.
Performance Over six months the shares gained 7.8%, against +4.9% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 7th highest of 14 in its peer set.
Growth Revenue grew 6.5% over the last twelve months (peer median +4.7%); the operating margin is 4.8% (peer median 2.9%).
Valuation It trades at 23.4× forward earnings against a peer median of 15.7× (2nd most expensive of 12).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is +3 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.6 points above its cost of capital (5.0% WACC).
Next results Next results expected around 9 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 4.28B | CHF 4.14B | CHF 3.92B | CHF 3.75B | CHF 3.59B |
| Revenue growth | — | +5% | +5% | +4% | — |
| Gross profit | CHF 421M | CHF 429M | CHF 395M | CHF 388M | CHF 360M |
| EBITDA | CHF 349M | CHF 339M | CHF 311M | CHF 288M | CHF 282M |
| Net income | CHF 159M | CHF 181M | CHF 183M | CHF 174M | CHF 165M |
| Free cash flow | CHF 220M | CHF 272M | CHF 228M | CHF 181M | CHF 196M |
| Capital expenditure | CHF 60.6M | CHF 55.8M | CHF 72.4M | CHF 76.4M | CHF 69.8M |
| Total debt | n/a | CHF 1.06B | CHF 834M | CHF 775M | CHF 686M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GALE.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.0% | +3.6% | 5th highest of 14 |
| 6-month return | +7.8% | +4.9% | 7th highest of 14 |
| Distance from 52-week high | -13.2% | -14.9% | 6th highest of 14 |
| Revenue growth (TTM) | +6.5% | +4.7% | 5th highest of 14 |
| Operating margin | 4.8% | 2.9% | 4th highest of 14 |
| Forward P/E | 23.4× | 15.7× | 2nd most expensive of 12 |
| Growth the price implies (Req g, 7 yrs) | 6.9% | -1.4% | 4th most demanding of 12 |
| Growth delivered (Del g) | +3.5% | +5.1% | 3rd lowest of 12 |
| Hurdle (Req g minus delivered) | +3.4 pp | -11.0 pp | 3rd most demanding of 12 |
| ROIC minus cost of capital | +1.6 pp | +0.3 pp | 7th highest of 14 |
| EV / EBITDA | 15.9× | 8.4× | most expensive of 4 |
| Net debt / EBITDA | 3.1× | 0.5× | 3rd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Galenica GALE.SW | Switzerland | $5.46B | +8% | +6% | 5% | 23.4× | 6.9% | +3.5% |
| DKSH DKSH.SW | Switzerland | $6.10B | +29% | -1% | 3% | 21.5× | -1.4% | +0.6% |
| Sinopharm 1099.HK | Hong Kong | $6.83B | -4% | +3% | 3% | 6.3× | -8.1% | +4.0% |
| Jointown Pharmaceutical 600998.SS | China | $3.96B | +1% | +9% | 2% | 11.7× | 0.1% | +7.8% |
| Amplifon AMP.MI | Italy | $3.72B | +13% | 0% | 9% | 18.1× | 9.5% | +9.8% |
| MEDIPAL 7459.T | Japan | $3.67B | +14% | +4% | 1% | 12.6× | -7.4% | +3.5% |
| COSMOS Pharmaceutical 3349.T | Japan | $3.20B | +5% | +9% | 4% | 15.7× | n/a | n/a |
| Henry Schein HSIC | United States | $9.51B | +22% | +6% | 6% | 14.8× | 9.8% | +5.4% |
| Asker Healthcare ASKER.ST | Sweden | $2.98B | -5% | +12% | 7% | 26.6× | 1.2% | +12.7% |
| Alfresa 2784.T | Japan | $2.79B | -3% | +5% | 1% | 17.4× | -9.1% | +3.5% |
| Hanmi Science 008930.KS | South Korea | $2.71B | +44% | +6% | 5% | n/a | 24.2% | +9.6% |
| Suzuken 9987.T | Japan | $2.29B | -9% | +5% | 1% | 15.0× | -11.9% | +3.2% |
| Redcare Pharmacy RDC.DE | Germany | $1.63B | +52% | +19% | 0% | n/a | n/a | n/a |
| Toho 8129.T | Japan | $1.60B | -14% | +4% | 1% | 21.6× | -7.4% | +5.1% |